HOXDeRNA promoted astrocyte transformation by releasing PRC2 repression at glioma transcription factor promoters (SOX2, OLIG2) and activating super enhancers, leading to oncogene upregulation [17]. Here, SOX2 is linked to central nervous system cancer.